Established Models and New Paradigms for Hypoxia-Driven Cancer-Associated Bone Disease.

Abstract

The five-year survival rate for primary bone cancers is ~ 70% while almost all cases of secondary metastatic bone cancer are terminal. Hypoxia, the deficiency of oxygen which occurs as the rate of tumour growth exceeds the supply of vascularisation, is a key promoter of tumour progression. Hypoxia-driven effects in the primary tumour are wide ranging including changes in gene expression, dysregulation of signalling pathways, resistance to chemotherapy, neovascularisation, increased tumour cell proliferation and migration. Paget's seed and soil theory states that for a metastasising tumour cell 'the seed' it requires the correct microenvironment 'soil' to colonise. Why and how metastasising tumour cells colonise the bone is a complex and intriguing problem. However, once present tumour cells are able to disrupt bone homeostasis through increasing osteoclast activity and downregulating osteoblast function. Osteoclast resorption releases growth factors from the bone matrix that subsequently contribute to the proliferation of invasive tumour cells creating the vicious cycle of bone loss and metastatic cancer progression. Recently, we have shown that hypoxia increases expression and release of lysyl oxidase (LOX) from primary mammary tumours, which in turn disrupts bone homeostasis to favour osteolytic degradation to create pre-metastatic niches in the bone microenvironment. We also demonstrated how treatment with bisphosphonates could block this cancer-induced bone remodelling and reduce secondary bone metastases. This review describes the roles of hypoxia in primary tumour progression to metastasis, with a focus on key signalling pathways and treatment options to reduce patient morbidity and increase survival.

• Authors: Thomas R Cox, Janine T Erler, Robin M H Rumney
• Journal: Calcified tissue international (Calcif Tissue Int) Vol. 102 Issue 2 Pg. 163-173 (02 2018) ISSN: 1432-0827 [Electronic] United States
• PMID: 29098360 (Publication Type: Journal Article, Review)

Chemical References

• Neuropeptide Y
• Protein-Lysine 6-Oxidase
• Dipeptidyl Peptidase 4

Topics

• Bone Neoplasms (epidemiology, etiology, secondary, therapy)
• Breast Neoplasms (pathology)
• Cell Hypoxia
• Dipeptidyl Peptidase 4 (metabolism)
• Disease Progression
• Female
• Humans
• Models, Biological
• Multiple Myeloma (pathology)
• Neuropeptide Y (physiology)
• Protein-Lysine 6-Oxidase (physiology)